Ruplizumab

Summary

Ruplizumab (CHEMBL2108767) is a phase-3 clinical-stage antibody; indicated across 1 condition including lupus nephritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108767
Name	Ruplizumab
Type	Antibody
Max phase	3

Also known as: Antova, BG-9588, BG9588, HU-5C8, Ruplizumab, hu5c8, RUPLIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lupus nephritis	2	MONDO:0005556	EFO:0005761

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001789	PHASE2	COMPLETED	BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
NCT00001857	PHASE2	COMPLETED	Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).